Precision Wealth Strategies LLC acquired a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 14,063 shares of the company’s stock, valued at approximately $677,000.
A number of other institutional investors have also recently bought and sold shares of KNSA. EverSource Wealth Advisors LLC grew its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. Institutional investors own 53.95% of the company’s stock.
Analyst Ratings Changes
KNSA has been the topic of a number of recent research reports. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Buy” and a consensus target price of $65.14.
Kiniksa Pharmaceuticals International Trading Up 4.6%
NASDAQ KNSA opened at $63.95 on Friday. The firm’s 50 day simple moving average is $56.42 and its 200 day simple moving average is $49.21. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of 71.06 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $26.27 and a 1 year high of $67.53.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. During the same period in the previous year, the business earned $0.11 earnings per share. The company’s revenue was up 55.5% on a year-over-year basis. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.25 earnings per share for the current year.
Insider Activity
In related news, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total value of $25,082,296.44. Following the completion of the transaction, the chief executive officer owned 431,904 shares in the company, valued at approximately $22,398,541.44. This represents a 52.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 628,427 shares of company stock worth $32,833,228. Insiders own 51.98% of the company’s stock.
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
